CCR2 and Nephropathy: Another trial involving patients with type 2 diabetes and nephropathy reported that changes in HbA1c, fasting plasma insulin and HOMA‐IR in response to a CCR2 inhibitor, CCX140‐B, were not significant compared with the response to the placebo.28